

Miquel Blasco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7558886/publications.pdf>

Version: 2024-02-01

70
papers

1,594
citations

361045

20
h-index

315357

38
g-index

73
all docs

73
docs citations

73
times ranked

2317
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 and influenza virus co-infection. <i>Lancet</i> , The, 2020, 395, e84.	6.3	161
2	Eculizumab in secondary atypical haemolytic uraemic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 466-474.	0.4	121
3	Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. <i>Kidney International</i> , 2018, 94, 408-418.	2.6	117
4	A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. <i>Kidney International</i> , 2018, 93, 450-459.	2.6	100
5	Situación de la infección por SARS-CoV-2 en pacientes en tratamiento renal sustitutivo. Informe del Registro COVID-19 de la Sociedad Española de Nefrología (SEN). <i>Nefrología</i> , 2020, 40, 272-278.	0.2	100
6	Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. <i>Kidney International</i> , 2017, 92, 953-963.	2.6	87
7	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. <i>Blood</i> , 2020, 136, 2103-2117.	0.6	82
8	Use of tocilizumab in kidney transplant recipients with COVID-19. <i>American Journal of Transplantation</i> , 2020, 20, 3182-3190.	2.6	72
9	Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy. <i>Transplantation</i> , 2015, 99, 1709-1714.	0.5	69
10	Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. <i>Kidney International Reports</i> , 2019, 4, 434-446.	0.4	59
11	Complement Activation and Thrombotic Microangiopathies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1719-1732.	2.2	57
12	Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. <i>Kidney International</i> , 2019, 96, 995-1004.	2.6	52
13	RICORS2040: the need for collaborative research in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 372-387.	1.4	45
14	Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). <i>Nefrología</i> , 2020, 40, 272-278.	0.2	35
15	Severe acute kidney injury in critically ill COVID-19 patients. <i>Journal of Nephrology</i> , 2021, 34, 285-293.	0.9	31
16	Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management. <i>Journal of Nephrology</i> , 2015, 28, 641-645.	0.9	29
17	Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1305-1311.	3.0	29
18	Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 28-30.	1.4	26

#	ARTICLE	IF	CITATIONS
19	Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy. CKJ: Clinical Kidney Journal, 2019, 12, 36-41.	1.4	25
20	Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics. Scientific Reports, 2021, 11, 3048.	1.6	25
21	ANCA associated vasculitis: The journey to complement-targeted therapies. Molecular Immunology, 2019, 112, 394-398.	1.0	23
22	Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. British Journal of Haematology, 2021, 193, 181-187.	1.2	20
23	The renal range of the β_2 -microglobulin/sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease. BMC Nephrology, 2020, 21, 111.	0.8	18
24	The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis. Journal of Nephrology, 2021, 34, 1897-1905.	0.9	18
25	Practical Utility of On-Line Clearance and Blood Temperature Monitors as Noninvasive Techniques to Measure Hemodialysis Blood Access Flow. Blood Purification, 2011, 31, 1-8.	0.9	16
26	Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. Oncoimmunology, 2018, 7, e1445952.	2.1	16
27	Anti-C5 as Prophylactic Therapy in Atypical Hemolytic Uremic Syndrome in Living-Related Kidney Transplantation. Transplantation, 2013, 96, e26-e29.	0.5	14
28	Thrombotic microangiopathies assessment: mind the complement. CKJ: Clinical Kidney Journal, 2021, 14, 1055-1066.	1.4	14
29	Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disorders. Autoimmunity Reviews, 2022, 21, 103014.	2.5	11
30	Complement Mediated Endothelial Damage in Thrombotic Microangiopathies. Frontiers in Medicine, 2022, 9, 811504.	1.2	11
31	Is ionic dialysance useful for early detection of vascular access dysfunction? Six illustrative cases. Hemodialysis International, 2011, 15, 108-111.	0.4	9
32	IgA Nephropathy Recurrence after Kidney Transplantation: Role of Recipient Age and Human Leukocyte Antigen-B Mismatch. American Journal of Nephrology, 2020, 51, 357-365.	1.4	8
33	Borderline rejection in ABO-incompatible kidney transplantation. Clinical Transplantation, 2016, 30, 872-879.	0.8	7
34	Desensitization in ABO-Incompatible Kidney Transplantation With Low ABO Iso-Agglutinin Titers. Transplantation Proceedings, 2015, 47, 2340-2343.	0.3	6
35	Clinical Impact of Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy in Critically Ill Patients. International Journal of Artificial Organs, 2017, 40, 676-682.	0.7	6
36	High cut-off membrane for in-vivo dialysis of free plasma hemoglobin in a patient with massive hemolysis. BMC Nephrology, 2018, 19, 250.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Recurrent acute interstitial nephritis: what lies beneath. CKJ: Clinical Kidney Journal, 2021, 14, 197-204.	1.4	6
38	The Interplay between Pathophysiological Pathways in Early-Onset Severe Preeclampsia Unveiled by Metabolomics. Life, 2022, 12, 86.	1.1	6
39	Thermodilution versus Saline Dilution Method for Vascular Access Blood Flow Measurement in High-Flux and On-Line Hemodiafiltration. Journal of Vascular Access, 2012, 13, 482-489.	0.5	5
40	Successful use of nonantigen-specific immunoadsorption with antihuman IgA columns in kidney graft antibody-mediated rejection. Journal of Clinical Apheresis, 2020, 35, 188-199.	0.7	5
41	Risk Factors for Acute Kidney Injury Following Cardiac Surgery and Performance of Leicester Score in a Spanish Cohort. Journal of Clinical Medicine, 2022, 11, 904.	1.0	5
42	Papel de la diálisis sostenida de baja eficiencia en las unidades de cuidados intensivos. Nefrología, 2019, 39, 98-99.	0.2	4
43	Hyperhemolytic Transfusion Reaction in Non-Hemoglobinopathy Patients and Terminal Complement Pathway Activation: Case Series and Review of the Literature. Transfusion Medicine Reviews, 2020, 34, 172-177.	0.9	4
44	An update on tolvaptan for autosomal dominant polycystic kidney disease. Drugs of Today, 2018, 54, 519.	0.7	4
45	The Density of Renal Lymphatics Correlates With Clinical Outcomes in IgA Nephropathy. Kidney International Reports, 2022, 7, 823-830.	0.4	4
46	Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplantation. Liver Transplantation, 2022, 28, 1332-1344.	1.3	4
47	The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation. CKJ: Clinical Kidney Journal, 2018, 11, 422-428.	1.4	3
48	Antiphospholipase A2 receptor antibody-positive membranous nephropathy in the kidney donor: Lessons from a serendipitous transplantation. American Journal of Transplantation, 2022, 22, 299-303.	2.6	3
49	Atypical hemolytic uraemic syndrome. Medicina Clínica (English Edition), 2015, 145, 438-445.	0.1	2
50	Management of Acute Renal Replacement therapy in critically ill cirrhotic patients. CKJ: Clinical Kidney Journal, 0, , .	1.4	2
51	Living donor kidney transplantation is an effective option of renal replacement therapy in patients with light-chain amyloidosis (AL). Annals of Hematology, 2020, 99, 2961-2962.	0.8	1
52	The Case Persistent fever in a hemodialysis patient. Kidney International, 2022, 101, 193-194.	2.6	1
53	Cloudy fluid, cloudy diagnosis. Peritoneal Dialysis International, 2022, 42, 643-646.	1.1	1
54	Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study. Journal of Clinical Medicine, 2022, 11, 2915.	1.0	1

#	ARTICLE	IF	CITATIONS
55	MP306EFFICACY AND SAFETY OF REGIONAL CITRATE ANTICOAGULATION IN CONTINUOUS HEMODIAFILTRATION IN CLINICAL PRACTICE. Nephrology Dialysis Transplantation, 2017, 32, iii538-iii538.	0.4	0
56	SP475ROLE OF SUSTAINED LOW EFFICIENCY DIALYSIS (SLED) IN CRITICALLY ILL PATIENTS IN A TERTIARY REFERRAL HOSPITAL. Nephrology Dialysis Transplantation, 2018, 33, i507-i507.	0.4	0
57	SP184CLINICAL IMPLICATIONS AND PATHOLOGICAL CLASSIFICATION OF TUBULOINTERSTITIAL INJURY FOR THE PREDICTION OF RENAL OUTCOME IN LUPUS NEPHRITIS. Nephrology Dialysis Transplantation, 2018, 33, i406-i406.	0.4	0
58	Six-2 glomerular expression for the prediction of renal outcome in systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 97-98.	1.4	0
59	SP059FIBROMUSCULAR DYSPLASIA: 40 YEARS OF EXPERIENCE IN A TERTIARY REFERRAL HOSPITAL. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
60	SP479IMPACT OF THE INTENSITY OF INTERMITTENT RENAL REPLACEMENT THERAPY IN THE CRITICAL ILL PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
61	FP213RECURRENT ACUTE INTERSTITIAL NEPHRITIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
62	P0485ASSOCIATION BETWEEN ANTI-GBM TITERS AND KIDNEY INFLAMMATION MEASURED BY A NEW ACTIVITY SCORE. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
63	Impact of the intensity of intermittent renal replacement therapy in critically ill patients. Journal of Nephrology, 2021, 34, 105-112.	0.9	0
64	Acute renal replacement therapy in critically ill octogenarian or older patients: prognostic factors and renal outcomes. Journal of Nephrology, 2021, 34, 1531-1536.	0.9	0
65	MO393ACUTE RENAL REPLACEMENT THERAPY IN CRITICAL ILL OCTOGENARIAN OR OLDER PATIENTS: PROGNOSTIC FACTORS AND RENAL OUTCOMES. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
66	Thrombotic Microangiopathy: a Challenging Diagnosis Always. Israel Medical Association Journal, 2016, 18, 437-438.	0.1	0
67	MO315: Risk Factors for CSA-AKI and Performance of Leicester Score in a Spanish Cohort. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
68	MO009: Creatine-Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
69	MO783: Reduction of the Incidence of Dialysis Catheter-Associated Bacteraemia in Intensive Care Units after Systematic Application of Taurolock in the Sealing of the Catheter. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
70	MO241: Nets and Terminal Complement Pathway as Potential Biomarkers for Complement Overactivation Assessment in Anca-Associated Vasculitis. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0